NVCR vs IART Stock Comparison: AI Score, Valuation, Performance and Upside
Novocure and Integra LifeSciences both serve the neuro-oncology and neurosurgery space, but Novocure is a narrower, innovation-driven company built around its differentiated tumor treating fields technology, while Integra LifeSciences is a diversified, established neurosurgery and tissue technology device maker.
NVCR offers exposure to a differentiated oncology treatment technology with meaningful label expansion optionality, while IART offers exposure to a diversified, more mature neurosurgery device franchise. The tradeoff is between concentrated innovation-driven upside and diversified operational stability.
IART holds the edge across 3 of 5 key metrics in this comparison. IART leads on both 1-year return (+7.96%) and forward P/E quality (6.46x vs -21.84x for NVCR), a relatively favorable combination of momentum and valuation. On fundamentals, NVCR is growing revenue faster (15.60%), while IART maintains the higher operating margin (9.62%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for NVCR (+52.23%) than for IART (+16.09%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a differentiated, non-invasive cancer treatment technology
- Believe label expansion into new tumor types can meaningfully grow the addressable patient population
- Are comfortable with the concentration risk of a narrower set of approved oncology indications
- See continued international reimbursement expansion as a durable growth driver
- Prefer a diversified, established neurosurgery and tissue technology device portfolio
- Value long-standing hospital and physician relationships built over many years
- Want exposure to specialty medtech without the concentration risk of a single treatment technology
- Believe margin recovery from past manufacturing challenges can drive earnings improvement
| Metric | NVCR | IART |
|---|---|---|
| AI scorei | 35.2 | 25.2 |
| AI ranki | #1641 | #2927 |
| Latest closei | $13.15 | $12.75 |
| 1M returni | -17.55% | -21.68% |
| 3M returni | -11.39% | -23.42% |
| 6M returni | -20.88% | +16.44% |
| 1Y returni | +2.57% | +7.96% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | NVCR | IART |
|---|---|---|
| 1Y ago | $10.26K (+2.6%) started 2025-10-30 | $10.8K (+8.0%) started 2025-10-30 |
| 5Y ago | $1.22K (-87.8%) started 2021-11-01 | $1.9K (-81.0%) started 2021-11-01 |
| 10Y ago | $21.74K (+117.4%) started 2016-10-31 | $3.21K (-67.9%) started 2016-10-31 |
Hypothetical — past performance does not guarantee future results.
| Metric | NVCR | IART |
|---|---|---|
| Market capi | $2.08B | $1.31B |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | -21.84 | 6.46 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 2.60 | 1.86 |
| Analyst targeti | $27.14 | $19.56 |
| Target upsidei | +52.23% | +16.09% |
| Metric | NVCR | IART |
|---|---|---|
| Revenue growthi | 15.60% | 0.80% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | +3.26% | +5.73% |
| Operating margini | -5.75% | 9.62% |
| Profit margini | -21.25% | -0.44% |
| ROIC proxyi | -43.22% | -0.70% |
| Return on equityi | -43.22% | -0.70% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.98 | 1.21 |
| Debt/equityi | 69.04 | 196.49 |
| Current ratioi | 2.89 | 3.60 |
| Quick ratioi | 2.66 | 1.64 |
Over the past year, NVCR and IART have moved weakly in the same direction (correlation of 0.17), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | NVCR | IART |
|---|---|---|---|
| 1Y | Growthi | +2.57% | +7.96% |
| CAGRi | +2.58% | +7.97% | |
| Volatilityi | 80.20% | 60.09% | |
| Sharpe ratioi | 0.36 | 0.36 | |
| Sortino ratioi | 0.61 | 0.52 | |
| Max drawdowni | 34.42% | 40.35% | |
| Current drawdowni | 34.22% | 35.77% | |
| Avg drawdowni | 13.91% | 14.85% | |
| Ulcer Indexi | 16.60% | 19.03% | |
| Max daily dropi | 20.00% | 21.19% | |
| Max wkly dropi | 23.81% | 21.34% | |
| 5Y | Growthi | -87.82% | -81.03% |
| CAGRi | -34.40% | -28.31% | |
| Volatilityi | 81.45% | 49.73% | |
| Sharpe ratioi | -0.18 | -0.51 | |
| Sortino ratioi | -0.28 | -0.68 | |
| Max drawdowni | 91.56% | 87.85% | |
| Current drawdowni | 88.93% | 82.59% | |
| Avg drawdowni | 68.47% | 53.27% | |
| Ulcer Indexi | 73.00% | 59.11% | |
| Max daily dropi | 43.04% | 23.46% | |
| Max wkly dropi | 46.39% | 27.87% | |
| 10Y | Growthi | +117.36% | -67.93% |
| CAGRi | +8.08% | -10.75% | |
| Volatilityi | 72.24% | 41.44% | |
| Sharpe ratioi | 0.39 | -0.17 | |
| Sortino ratioi | 0.63 | -0.23 | |
| Max drawdowni | 95.55% | 88.39% | |
| Current drawdowni | 94.17% | 83.36% | |
| Avg drawdowni | 49.16% | 33.93% | |
| Ulcer Indexi | 61.47% | 44.25% | |
| Max daily dropi | 43.04% | 23.46% | |
| Max wkly dropi | 46.39% | 27.87% |
| Category | NVCR | IART |
|---|---|---|
| Company | Novocure Limited | Integra LifeSciences Holdings Corporation |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | A commercial-stage oncology company that develops tumor treating fields therapy, a wearable, non-invasive treatment approach that uses electric fields to disrupt cancer cell division across several tumor types. | A medical technology company that designs and manufactures products for neurosurgery, tissue reconstruction, and wound care, serving hospitals and surgical specialists across multiple established device categories. |
| Investor focus | Label expansion into new tumor types, patient adherence and device utilization rates, and reimbursement approval progress across international markets. | Organic growth across neurosurgery and tissue technology segments, manufacturing quality and supply chain execution, and margin recovery following past operational challenges. |
- Differentiated, non-invasive tumor treating fields technology addresses cancers with historically limited treatment options
- Ongoing label expansion into additional tumor types offers a pathway to a substantially larger addressable patient population
- Established reimbursement coverage in key markets provides a foundation for continued international expansion
- Diversified portfolio across neurosurgery, tissue reconstruction, and wound care spreads revenue across multiple established device categories
- Long-standing relationships with hospital systems and neurosurgeons support steady demand for core surgical products
- Broad global distribution network supports consistent product availability across many healthcare markets
- Patient adherence to the wearable device regimen is critical to demonstrating treatment efficacy and supporting continued reimbursement
- Pipeline expansion into new cancer indications depends on clinical trial outcomes that remain inherently uncertain
- Revenue remains concentrated in a narrower set of approved indications relative to broadly diversified oncology device companies
- Past manufacturing and quality control issues have required ongoing remediation investment and management attention
- Slower organic growth compared to higher-growth specialty medtech names limits the pace of margin expansion
- Competitive pressure across multiple established device categories requires continued innovation to defend market share
Compare more than two at a time
This page is a fixed writeup on NVCR and IART. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside NVCR and IART, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.